C19orf77 Inhibitors
C19orf77 inhibitors target a wide range of cellular signaling pathways and enzymes, thus providing a multifaceted approach to the reduction of C19orf77 activity. Staurosporine, as a kinase inhibitor, could impede the activation of C19orf77 through the suppression of phosphorylation processes. LY294002 and Wortmannin, as PI3K inhibitors, potentially diminish the PI3K-AKT signaling, crucial for key post-translational modifications or the localization of C19orf77 that are required for its activity. The inhibition of PI3K by these compounds might lead to a cellular state in which C19orf77 is less active due to a lack of activation signals or improper cellular localization.
Additionally, compounds like U0126 and PD98059 that inhibit MEK1/2 could block the MAPK/ERK pathway, which might be necessary for the phosphorylation-based activation of C19orf77. Rapamycin, by inhibiting mTOR, may disrupt the synthesis of proteins that interact with or regulate C19orf77, thus diminishing its activity. SB203580 and SP600125 target the p38 MAP kinase and JNK, respectively, indicating that the stress response and transcriptional regulation pathways they control could be essential for the activation state of C19orf77. Inhibitors such as Go6983, Chelerythrine, and GF109203X diminish PKC activity, which might be vital for maintaining the signaling milieu necessary for C19orf77's action.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, which can lead to the inhibition of downstream signaling pathways that are essential for the activity of C19orf77. By inhibiting these kinases, the phosphorylation status of proteins that interact with or regulate C19orf77 can be altered, leading to a reduction in its functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. Since PI3K signaling affects numerous cellular processes including those related to membrane trafficking, vesicle sorting and intracellular signaling, the inhibition of PI3K can alter the cellular milieu in which C19orf77 operates, resulting in its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin selectively inhibits mTOR (mechanistic target of rapamycin), which is a central regulator of cell growth and proliferation. By inhibiting mTOR, rapamycin can indirectly decrease the activity of C19orf77 by disrupting processes that are necessary for its function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK, a kinase in the MAPK/ERK pathway. This pathway is involved in the regulation of cell division, and its inhibition can alter the cellular context in which C19orf77 functions, potentially reducing its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase, which is involved in the stress response. By inhibiting p38 MAP kinase, SB203580 can interfere with the signaling context required for C19orf77 to maintain its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that specifically blocks the MAPK/ERK pathway. By inhibiting this pathway, PD98059 can decrease the phosphorylation state of proteins that may be involved in the regulation of C19orf77, thereby decreasing its function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. By inhibiting PI3K, wortmannin can disrupt various signaling pathways and cellular processes that could be essential for the proper function of C19orf77, leading to its inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). Inhibition of JNK can impact cell differentiation and apoptosis, processes that could be crucial for the functional activity of C19orf77, resulting in its inhibition. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go6983 is a pan-kinase inhibitor that can inhibit protein kinase C (PKC). PKC plays a role in the regulation of several signaling pathways that may intersect with the functional activity of C19orf77. Inhibition of PKC can thus indirectly inhibit C19orf77. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src-family kinase inhibitor. Src kinases are involved in various signaling pathways that can regulate the activity of a wide array of proteins. Inhibiting these kinases can thus affect the functional state of C19orf77. | ||||||